15 April 2025

EU-RESPONSE at ECCMID 2025

EU-RESPONSE was represented at the 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID), held in Vienna from 11 to 15 April 2025.

An oral presentation titled “Pharmacokinetics and immunogenicity of AZD7442 (tixagevimab/cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial” was delivered by Clément Massonnaud.

Conclusions:
To our knowledge, this is the first study to report the pharmacokinetics and immunogenicity of AZD7442 in a large cohort of hospitalized COVID-19 patients with long-term follow-up. The incidence of anti-drug antibodies (TE-ADA positivity) did not appear to impact the pharmacokinetics of AZD7442.